Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval
Executive Summary
Keeping track of US FDA approvals last week included watching the creative and the familiar.
You may also be interested in...
A Baker’s Dozen Of US FDA Efficacy Approvals Using Real World Evidence
Fresenius Kabi’s Omegaven is most recent of 13 approvals, including three with breakthrough therapy designations, where FDA has relied on real world evidence to make a regulatory decision about efficacy.
FDA Flags Lower Efficacy For Merck's Keytruda, Roche's Tecentriq In Frontline Bladder Cancer Trials
In patients with previously untreated metastatic bladder cancer with low PD-L1 expression, PD-1 drugs alone don't work as well as chemo.
US FDA Outlines Streamlined Development Path For Targeted Therapies
But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.